Dina Bassiouny

Dina Bassiouny

Auto-generated profile, based on publicly available information

Dina Bassiouny

Department of Anatomic Pathology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
CPCarlos Parra-Herran
Carlos Parra-Herran
JLJordan Lerner-Ellis
Jordan Lerner-Ellis
BXBin Xu
Bin Xu
SKSam Khalouei
Sam Khalouei
DBDina Bassiouny
Dina Bassiouny
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
The Cancer Genome Atlas classification divides endometrial carcinoma in biologically distinct groups, and testing for p53, mismatch repair proteins (MMR), and polymerase ɛ (POLE) exonuclease domain mutations has been shown to predict the molecular subgroup and clinical outcome. While abnormalities in these markers have been described in ovarian endometrioid carcinoma, their role in predicting its molecular profile and prognosis is still not fully explored. Patients with ovarian endometrioid carcinomas treated surgically in a 14-year period were selected. Only tumors with confirmation of endometrioid histology and negative WT1 and Napsin-A were included. POLE mutational analysis and immunohistochemistry for p53, MLH1, MSH2, MSH6, and PMS2 was performed in formalin-fixed, paraffin-embedded tissue. Following the molecular classifier proposed for endometrial carcinoma (Br J Cancer2015;113:299–310), cases were classified as POLE mutated, MMR abnormal, p53 abnormal, and p53 wild type. Clinicopathologic information was recorded, including patient outcome. In all, 72 cases were included, distributed as follows: 7 (10%) POLE mutated; 6 (8%) MMR abnormal; 17 (24%) p53 abnormal; and 42 (58%) p53 wild type. The molecular classification correlated with disease-free survival in multivariate analysis (P=0.003), independently of tumor grade and stage. Correlation with overall survival approached statistical significance (P=0.051). POLE-mutated and MMR-abnormal tumors had excellent survival, whereas p53-abnormal tumors had significantly higher rates of recurrence and death. Ovarian endometroid carcinoma can be classified in clinically meaningful subgroups by testing for molecular surrogates, akin to endometrial cancer. MMR and POLE alterations seem to identify a subset of ovarian endometrioid carcinomas with excellent outcome; conversely, abnormal p53 carries a worse prognosis. In the era of personalized medicine, the use of these markers in the routine evaluation of ovarian endometrioid tumors should be considered.

1 November 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
LHLiat Hogen
Liat Hogen
GTGillian Thomas
Gillian Thomas
MBMarcus Bernardini
Marcus Bernardini
DBDina Bassiouny
Dina Bassiouny
HBHarinder Brar
Harinder Brar
DVDanielle Vicus
Danielle Vicus

16 January 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
DBDina Bassiouny
Dina Bassiouny
NINadia Ismiil
Nadia Ismiil
VDValerie Dubé
Valerie Dubé
GHGuangming Han
Guangming Han
MCMatthew Cesari
Matthew Cesari
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

1 October 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
LHLiat Hogen
Liat Hogen
HBHarry Brar
Harry Brar
ACAllan Covens
Allan Covens
DBDina Bassiouny
Dina Bassiouny
MBMarcus Q. Bernardini
Marcus Q. Bernardini
DVDanielle Vicus
Danielle Vicus

17 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MMMatthew McNeil
Matthew McNeil
VRVishwesh Ramanathan
Vishwesh Ramanathan
DBDina Bassiouny
Dina Bassiouny
SNSharon Nofech-Mozes
Sharon Nofech-Mozes
EREileen Rakovitch
Eileen Rakovitch
AMAnne Martel
Anne Martel
Background: Although DCIS has a relatively low recurrence rate, many patients still receive adjuvant radiotherapy or endocrine therapy, raising concerns about overtreatment. Reliable biomarkers are therefore needed to predict an individual patient’s risk and guide treatment decisions. Recent studies suggest that the composition of the tumour-associated stroma (TAS) affects progression and outcome, highlighting TAS-derived biomarkers as promising candidates for further investigation. Methods: We trained AI models for cell and tumour segmentation using whole slide digital pathology images acquired as part of a retrospective cohort study. We investigated the effects of cell density within both the tumour and the TAS to determine how they correlated with recurrence in the ipsilateral breast. Results: We found that the concentration of DCIS lesions on the slide and the density of mitotic figures inside the TAS region were significantly associated with recurrence risk. Additionally, we found some predictive value in the lymphocyte and red blood cell densities in different tumour regions. Stromal composition was shown to associate with recurrence risk, and density-based biomarkers were identified and used to cluster patients into phenotypes with significantly different risk profiles. Conclusion: Our findings highlight the prognostic relevance of stromal composition in DCIS, and we identify novel density-based biomarkers that can be used to identify patients who are more likely to experience a local recurrence after breast-conserving surgery alone. These results may aid in developing future risk-stratification tools for breast cancer patients, thereby reducing overtreatment and improving patient care.